Volume 13, Issue 2, Pages 196-206 (February 2012) Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial  Dr Ralf Trappe, MD, Stephan Oertel, MD, Prof Veronique Leblond, MD, Peter Mollee, MBBS, Monica Sender, MD, Prof Petra Reinke, MD, Ruth Neuhaus, MD, Hans Lehmkuhl, MD, Prof Heinz August Horst, MD, Prof Gilles Salles, MD, Franck Morschhauser, MD, Prof Arnaud Jaccard, MD, Prof Thierry Lamy, MD, Malte Leithäuser, MD, Heiner Zimmermann, MB BChir, Prof Ioannis Anagnostopoulos, MD, Prof Martine Raphael, MD, Prof Hanno Riess, MD, Sylvain Choquet, MD  The Lancet Oncology  Volume 13, Issue 2, Pages 196-206 (February 2012) DOI: 10.1016/S1470-2045(11)70300-X Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile TTP=time to progression. PFS=progression-free survival. OS=overall survival. PLTD=post-transplant lymphoproliferative disorder. ECOG=Eastern Cooperative Oncology Group performance status. SOT=solid-organ transplantation. PR=partial remission. The Lancet Oncology 2012 13, 196-206DOI: (10.1016/S1470-2045(11)70300-X) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 2 Response duration, time to progression, overall survival, and progression-free survival Median time of follow-up was 5·1 years (IQR 1·62–5·93). Out of the final three deaths during the study period, only one was due to PTLD relapse, whereas two were not disease-related. (A) Durable disease response (patients in complete remission or partial remission). (B) Time to progression (all patients). (C) Overall survival. (D) Progression-free survival. The Lancet Oncology 2012 13, 196-206DOI: (10.1016/S1470-2045(11)70300-X) Copyright © 2012 Elsevier Ltd Terms and Conditions